Effect of DcR3 on Animal Models of Liver Fibrosis

PAN Liu-Lan,JIA Sheng-Nan,ZHANG Qian,ILU Si-Qi,SHAO Xue,JIN Zhen-Jing
DOI: https://doi.org/10.3969/j.issn.1000-484x.2016.11.005
2016-01-01
Abstract:Objective:To study the preventive therapy effect on DcR 3 gene on hepatic fibrosis rats.Methods:30 healthy male Wistar rats were divided into 3 groups randomly which weight were 180-200 g:control group ,DcR3 treatment group and hepatic fibrosis group.Hepatic fibrosis was induced by 1% DMN intraperitoneal injection in hepatic fibrosis group and DcR 3 treatment group.The plasmid transfected DcR3 was intraperitoneal injected in DcR 3 group.All rats were killed at the end of 4th week.Then the livers pathology were used to make HE and Masson staining.The mRNA and protein level of DcR3,Fas,FasL,α-SMA and TGF-β1 were measured by qRT-PCR and Western blot respectively.Results: Compared with model group , DcR3 improved the inflammatory cell infiltration and collagen deposition of liver in the rats of the DcR 3 group.The mRNA and protein level of Fas ,FasL,α-SMA and TGF-β1 were significantly reduced in DcR3 group compared with hepatic fibrosis group (P<0.05).Meanwhile,the mRNA and protein levels of DcR3 was significant increase in DcR3 group ( P<0.05).Conclusion:DcR3 could inhibit hepatic fibrosis efficiently by reducing the inflammatory response and collagen deposition , suppressing the expression of α-SMA and TGF-β1, inhibiting HSC activin, down-regulating Fas/FasL and suppressing the hepatocyte apoptosis induced by Fas /FasL pathway.
What problem does this paper attempt to address?